BioXcel Therapeutics strengthens cash position to advance SERENITY trial

BioXcel Therapeutics (BTAI) announced that, following the successful raise of $14 million gross proceeds in an equity financing that closed on March 4, 2025, it has approximately $35 million in cash. The strengthened cash position will support continued advancement of the Company’s pivotal Phase 3 SERENITY At-Home trial. The trial is designed to evaluate the safety of BXCL501. “We are pleased the recent financing enables us to progress our SERENITY At-Home trial,” said Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics. “Patient enrollment is continuing and topline data results expected in the second half of 2025 are intended to support a potential sNDA submission to expand the label for IGALMI(R) in the at-home setting. We are highly motivated by the prospect of bringing – for the first time – an acute treatment option for agitation to millions of additional patients in this setting.”